The Eris Lifesciences IPO is a closed mainboard Bookbuilding offer (Offer For Sale) that opened on 16 June 2017. The Eris Lifesciences IPO closed on 20 June 2017, with an issue price of ₹603 per share. The Eris Lifesciences IPO has a face value of ₹1 and a lot size of 24 shares. The Eris Lifesciences IPO is listed on 29 June 2017. The Eris Lifesciences IPO allotment was scheduled for 23 June 2017.
On the financial front, the Eris Lifesciences IPO reported revenue of ₹597 crore for 31-Mar-16, compared with ₹546 crore for 31-Mar-15. The Eris Lifesciences IPO PAT was ₹135 crore against ₹89 crore.
Always verify The Eris Lifesciences IPO details and GMP data with the official offer document before investing in the Eris Lifesciences IPO.
Financial Summary
Amount In Crore
Metric
31-Mar-16
31-Mar-15
31-Mar-14
Total Assets
397
357
271
Revenue
597
546
509
PAT
135
89
71
Eris Lifesciences IPO Financials FAQs
Revenue of Eris Lifesciences (Amount In Crore) — 31-Mar-16: 597; 31-Mar-15: 546; 31-Mar-14: 509. Profit after tax (PAT) — 31-Mar-16: 135; 31-Mar-15: 89; 31-Mar-14: 71.
Total assets — 31-Mar-16: 397; 31-Mar-15: 357; 31-Mar-14: 271. (Amount In Crore)
The financials shown for Eris Lifesciences IPO are taken from the company's offer document (DRHP/RHP/prospectus) filed with the exchange and SEBI, and are updated here when restated figures are published. Always cross-check with the official offer document before investing.
Look at the trend of revenue and PAT across periods, whether EBITDA is growing along with revenue, and whether net worth is rising while borrowings stay under control. The first column may be a part-year (interim) period, so compare full financial years with each other.
GMP and IPO data are unofficial and for information only — not investment advice.
Read the full disclaimer.
